USSTOCK.TODAY
Regular Market
Log in Sign up

Recursion Pharmaceuticals Extends Financial Runway to 2029 and Shifts Operational Focus

The Motley Fool +1 · ·by G4L

RXRX
RXRX Recursion Pharmaceuticals Inc
$3.81 +8.10%
View chart & analysis →
  1. 1Recursion Pharmaceuticals completed a $200 million oversubscribed financing in October.
  2. 2Recursion recorded $535 million in cash inflows from its partners.
  3. 3REC-4881 clinical results showed 87% of evaluable patients experienced a reduction in total polyp burden after 12 weeks of treatment.

So what's the key point?

Recursion Pharmaceuticals secured funds to support operations through 2029. The company also collected $535 million in cash and confirmed positive results during the drug development process.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Recursion Pharmaceuticals Beats Revenue Estimates and Secures Funding Through 2029 Earnings Whispers · 5d agoFTC and 7 States Seek Contempt Charges Against Martin Shkreli, Banned from Pharmaceutical Industry Investing.com +2 · Oct 13Recursion Pharmaceuticals posts Q2 loss of $131 million, missing estimates Associated Press +1 · Aug 5
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news